Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...

New drug offers hope for patients with Schizophrenia that has long eluded effective treatment. Read on to know more.

While momentous, the approval of Cobenfy could also draw attention to an age-old problem in American healthcare: Will insurance barriers keep patients from getting an effective medicine?

Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in ...

People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...

Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...

A new drug has been approved for the treatment of schizophrenia in adults. On Thursday, the U.S. Food and Drug Administration (FDA) approved COBENFY (xanomeline and trospium chloride), an oral ...

Despite the seriousness of this condition, treatment can make it possible for you or a loved one with schizophrenia to manage the symptoms and have meaningful relationships, go to work or school ...

The company will halt further development of luvadaxistat and focus on another schizophrenia candidate ... of subjects enrolled across the treatment arms. Also Read: Neurocrine Biosciences ...

we understand the challenges and hurdles that exist in identifying potential medicines for the treatment of cognitive impairment in schizophrenia. “We, therefore, plan to halt further ...

Neurocrine Biosciences said its trial of luvadaxistat as a potential treatment to improve cognitive impairment in patients with schizophrenia failed to meet its primary endpoint. The San Diego ...

The dopamine hypothesis of schizophrenia is a scientific theory that suggests dopamine directly contributes to schizophrenia symptoms. Research on this theory and other causes of schizophrenia is ...